Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

Go back to Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
(NASDAQ: SION) Delayed: 3.87 -0.28 (6.75%)
Previous Close $4.15    52 Week High $ 
Open $4.20    52 Week Low $ 
Day High $4.31    P/E N/A 
Day Low $3.86    EPS $ 
Volume 1,557,306